Benitec Biopharma is a development-stage biotechnology company focused on the development of genetic medicines. Co. is developing DNA-directed RNA interference-based therapeutics for chronic and life-threatening clinical indications including Oculopharyngeal Muscular Dystrophy (OPMD), a genetic disorder. BB-301 is under development for the treatment of OPMD and is undergoing evaluation in Clinical Trial Application-enabling and Investigational New Drug-enabling studies. BB-301 is designed to correct the genetic defect underlying OPMD following a single localized administration. The BNTC stock yearly return is shown above.
The yearly return on the BNTC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BNTC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|